Compare BEAT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAT | NSRX |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 63.4M |
| IPO Year | 2021 | 2025 |
| Metric | BEAT | NSRX |
|---|---|---|
| Price | $2.59 | $6.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.75 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 37.0M | 3.5K |
| Earning Date | 11-13-2025 | 01-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $5.90 |
| 52 Week High | $4.00 | $9.99 |
| Indicator | BEAT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | N/A |
| Support Level | $2.50 | N/A |
| Resistance Level | $3.18 | N/A |
| Average True Range (ATR) | 0.58 | 0.00 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 58.95 | 0.00 |
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.